OPTUS Pharmaceutical Co., Ltd. (KOSDAQ:131030)
South Korea · Delayed Price · Currency is KRW 7,580.00
+180.00 (2.43%)
At close: Jan 23, 2026
OPTUS Pharmaceutical Revenue
OPTUS Pharmaceutical had revenue of 24.07B KRW in the quarter ending September 30, 2025, with 24.67% growth. This brings the company's revenue in the last twelve months to 87.58B, up 11.13% year-over-year. In the year 2024, OPTUS Pharmaceutical had annual revenue of 81.90B with 13.09% growth.
Revenue (ttm)
87.58B
Revenue Growth
+11.13%
P/S Ratio
1.53
Revenue / Employee
550.80M
Employees
159
Market Cap
133.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 81.90B | 9.48B | 13.09% |
| Dec 31, 2023 | 72.43B | 13.77B | 23.47% |
| Dec 31, 2022 | 58.66B | 1.34B | 2.34% |
| Dec 31, 2021 | 57.32B | -3.51B | -5.77% |
| Dec 31, 2020 | 60.83B | 385.58M | 0.64% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| H.PIO | 257.56B |
| DongKoo Bio & Pharma | 238.39B |
| Kyung Dong Pharmaceutical | 193.64B |
| GREEN CROSS WellBeing | 151.06B |
| HYUNDAI BIOLAND | 129.68B |
| WITHUS PHARMACEUTICAL Co.,LTD. | 102.11B |
| KOREA PHARMA | 90.11B |
| Sam-A Pharm. | 76.66B |